

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person* Harper John Frederick	2. Date of Event Requiring Statement (Month/Day/Year) 09/30/2011	3. Issuer Name and Ticker or Trading Symbol AxoGen, Inc. [AXGN]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	5. If Amendment, Date Original Filed (Month/Day/Year) 10/11/2011
(Last) (First) (Middle) 13859 PROGRESS BLVD., SUITE 100			
(Street) ALACHUA, FL 32615			
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned		

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	55,416 (1) (2)	D	
Common Stock	86,557 (3)	I	Shares owned indirectly through Springboard Capital II, LLC. as a non-controlling limited partner

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	02/24/2011	02/24/2021	Common Stock	2,149 (4) (5) (6)	\$ 0.27 (7) (8)	D	
Stock Option (right to buy)	07/24/2009	07/24/2019	Common Stock	5,964 (6) (9)	\$ 0.27 (7) (8)	D	
Stock Option (right to buy)	06/20/2011	06/20/2021	Common Stock	4,210 (5) (6)	\$ 1.07 (7) (8)	D	
Stock Option (right to buy)	09/29/2011	09/29/2021	Common Stock	5,218 (5) (6)	\$ 1.07 (7) (8)	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Harper John Frederick 13859 PROGRESS BLVD., SUITE 100 ALACHUA, FL 32615	X			

Signatures

/s/ John Harper	04/10/2013
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Pursuant to an Agreement and Plan of Merger, dated as of May 31, 2011, by and among LecTec Corporation ("LecTec"), Nerve Merger Sub Corp., a subsidiary of LecTec ("Merger Sub"), and AxoGen Corporation ("AC"), which the parties amended on June 30, 2011 and August 9, 2011 (as amended, the "Merger Agreement"), Merger Sub
(1) merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the "Merger"). The Merger was completed on September 30, 2011, and LecTec was renamed AxoGen, Inc. ("AxoGen"). In connection with the Merger, each share of AC common stock converted into 0.03727336 share of LecTec common stock at the effective time of the Merger.
(2) Reflects 9,318 shares obtained as a result of an option exercise which was not reflected in original filing.
(3) Shares are owned indirectly through Springboard Capital II, LLC. as a non-controlling limited partner.
(4) 9,318 shares under option were included in original filing but had previously been exercised.
(5) These options have not vested.
(6) These shares vest annually over three years from grant date.
(7) Amended to correct mistake in option exercise price after appropriate application of conversion ratio as explained in footnotes.
(8) In connection with the Merger, each option to purchase shares of AC common stock was converted to an option to purchase 0.03727336 of a share of AxoGen common stock.
(9) 3,976 options have vested, and 1,988 options are unvested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.